Savara (SVRA) Capital Expenditures (2010 - 2026)
Savara (SVRA) reported Capital Expenditures of $54000.0 for Q1 2026, up 1700.0% year-over-year from $3000.0 in Q1 2025, and up 2600.0% on a QoQ basis from $2000.0 in Q4 2025.
Savara (SVRA) has 17 years of Capital Expenditures data on file, last reported at $54000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 1700.0% year-over-year to $54000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73000.0 (up 305.56% YoY) and the FY2025 annual result came in at $22000.0, down 12.0% from the prior year.
- Capital Expenditures rose to $54000.0 in Q1 2026 per SVRA's latest filing, from $2000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $225000.0 in Q2 2023 and bottomed at -$9000.0 in Q4 2024.
- The 5-year median for Capital Expenditures is $7000.0 (2022), against an average of $28642.9.
- The widest annual swing landed in 2024, when Capital Expenditures slumped 137.5%; it then soared 1700.0% in 2026.
- Tracing SVRA's Capital Expenditures over 5 years: stood at $4000.0 in 2022, then soared by 500.0% to $24000.0 in 2023, then tumbled by 137.5% to -$9000.0 in 2024, then soared by 122.22% to $2000.0 in 2025, then surged by 2600.0% to $54000.0 in 2026.
- Per Business Quant, the three latest SVRA Capital Expenditures figures stand at $54000.0 (Q1 2026), $2000.0 (Q4 2025), and $2000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54,000.00 |
| Mar 31, 2026 | 54,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Dec 31, 2024 | -9,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Dec 31, 2023 | 24,000.00 |
| Sep 30, 2023 | 43,000.00 |
| Sep 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 225,000.00 |
| Jun 30, 2023 | 225,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Dec 31, 2021 | 40,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Sep 30, 2021 | 11,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Dec 31, 2020 | 5,000.00 |
| Sep 30, 2020 | 18,000.00 |
| Sep 30, 2020 | 18,000.00 |
| Jun 30, 2020 | 20,000.00 |
| Jun 30, 2020 | 20,000.00 |
| Mar 31, 2020 | 4,000.00 |
| Mar 31, 2020 | 4,000.00 |
| Dec 31, 2019 | 10,000.00 |
| Dec 31, 2019 | 10,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Sep 30, 2019 | 6,000.00 |
| Jun 30, 2019 | 36,000.00 |
| Jun 30, 2019 | 36,000.00 |
| Mar 31, 2019 | 96,000.00 |
| Mar 31, 2019 | 96,000.00 |
| Dec 31, 2018 | 60,000.00 |
| Dec 31, 2018 | 60,000.00 |
| Sep 30, 2018 | 16,000.00 |
| Sep 30, 2018 | 16,000.00 |
| Jun 30, 2018 | 46,000.00 |
| Jun 30, 2018 | 46,000.00 |
| Mar 31, 2018 | 19,000.00 |
| Mar 31, 2018 | 19,000.00 |
| Dec 31, 2017 | 434,000.00 |
| Dec 31, 2017 | 434,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Jun 30, 2017 | 1,000.00 |
| Jun 30, 2017 | 1,000.00 |
| Mar 31, 2017 | 59,000.00 |
| Mar 31, 2017 | 59,000.00 |
| Sep 30, 2016 | 3,000.00 |
| Sep 30, 2016 | 3,000.00 |
| Mar 31, 2016 | 5,000.00 |
| Mar 31, 2016 | 5,000.00 |
| Dec 31, 2015 | 47,000.00 |
| Dec 31, 2015 | 47,000.00 |
| Sep 30, 2015 | 27,000.00 |
| Sep 30, 2015 | 27,000.00 |
| Jun 30, 2015 | 21,000.00 |
| Jun 30, 2015 | 21,000.00 |
| Mar 31, 2015 | 70,000.00 |
| Mar 31, 2015 | 70,000.00 |
| Dec 31, 2014 | 10,000.00 |
| Dec 31, 2014 | 10,000.00 |
| Sep 30, 2014 | 28,000.00 |
| Sep 30, 2014 | 28,000.00 |
| Jun 30, 2014 | 103,000.00 |
| Jun 30, 2014 | 103,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Mar 31, 2014 | 6,000.00 |
| Dec 31, 2013 | 1,652.00 |
| Dec 31, 2013 | 1,652.00 |
| Sep 30, 2013 | 28,172.00 |
| Sep 30, 2013 | 28,172.00 |
| Jun 30, 2013 | 12,451.00 |
| Jun 30, 2013 | 12,451.00 |
| Mar 31, 2013 | 4,725.00 |
| Mar 31, 2013 | 4,725.00 |
| Dec 31, 2012 | 55,266.00 |
| Dec 31, 2012 | 55,266.00 |
| Sep 30, 2012 | 4,993.00 |
| Sep 30, 2012 | 4,993.00 |
| Jun 30, 2012 | 18,553.00 |
| Jun 30, 2012 | 18,553.00 |
| Mar 31, 2012 | 187,363.00 |
| Mar 31, 2012 | 187,363.00 |
| Dec 31, 2011 | 202,780.00 |
| Dec 31, 2011 | 202,780.00 |
| Sep 30, 2011 | 184,444.00 |
| Sep 30, 2011 | 184,444.00 |
| Jun 30, 2011 | 9,680.00 |
| Jun 30, 2011 | 9,680.00 |
| Mar 31, 2011 | 14,858.00 |
| Mar 31, 2011 | 14,858.00 |
| Dec 31, 2010 | 21,733.00 |
| Dec 31, 2010 | 21,733.00 |